Skip to main content
. 2015 Jun;12(2):117–125. doi: 10.7497/j.issn.2095-3941.2015.0012

Figure 1.

Figure 1

Kaplan-Meier curves for PFS of 62 patients with stages I-IV CSCLC. The median PFS of 3-drug group was not significantly longer than that of 2-drug group (10.5 vs. 9.8 months, P=0.484). PFS, progression-free survival; CSCLC, combined small-cell lung cancer.